Suckling Keith
Expert Opin Investig Drugs. 2008 May;17(5):615-8. doi: 10.1517/13543784.17.5.615.
Whereas many new targets for drug discovery have been identified from new biology, such as that from the Human Genome Project, some targets have been known for decades but have not been exploited.
One such target, selective thyromimetics, is reviewed from a historical perspective and in the light of recent developments.
The history of thyromimetics in atherosclerosis and dyslipidaemia is reviewed as the background to the recent publication of the first human data on a new selective thyromimetic, KB-2115 (eprotirome).
The published data provide proof of concept/mechanism, opening the way to larger studies in a wider range of subjects and in combination with statins.
尽管从新生物学领域（如人类基因组计划）已确定了许多药物研发的新靶点，但有些靶点已被知晓数十年却未得到开发利用。
从历史角度并结合近期进展，对其中一个靶点——选择性甲状腺激素模拟物进行综述。
回顾甲状腺激素模拟物在动脉粥样硬化和血脂异常方面的历史，作为首个新型选择性甲状腺激素模拟物KB-2115（依普罗酮）的首批人体数据近期发表的背景。
已发表的数据提供了概念验证/作用机制，为在更广泛受试者中开展更大规模研究以及与他汀类药物联合使用开辟了道路。
